Fate Therapeutics, Inc.
Financials
Valuation Metrics
Fate Therapeutics, Inc.'s Market Cap is $243M. At end of 2025 it was $117M. Ranked #2941 of 3,114 in US market (top 94%), #1331 of 1,469 on NASDAQ (top 91%), #236 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $243M | US#2,941/3,114 Sec#236/265 |
| Revenue | $6M | US#2,819/3,114 Sec#175/265 |
| Net Income | $-126M | US—/3,114 Sec—/265 |
| Total Assets | $260M | US#2,937/3,114 Sec#221/265 |
| Net Assets | $153M | US#2,737/3,114 Sec#203/265 |
| Employees | 161 | US#2,522/3,114 Sec#139/265 |
| Value | ||
| P/B | 1.58x | US#1,012/3,114 Sec#46/265 |
| P/S | 37.38x | US#2,914/3,114 Sec#165/265 |
| FCF Yield | -43.55% | US—/3,114 Sec—/265 |
| Profitability | ||
| ROE | -82.12% | US#2,769/3,114 Sec#197/265 |
| ROA | -48.44% | US#2,981/3,114 Sec#210/265 |
| Op. Margin | -2058.08% | US#2,817/3,114 Sec#169/265 |
| Revenue Growth | -23.36% | US#2,658/3,114 Sec#152/265 |
| Financial Health | ||
| Debt Ratio | 69.52% | US#765/3,114 Sec#149/265 |
| Total Debt | $76M | US#2,509/3,114 Sec#132/265 |
| FCF | $-106M | US#2,647/3,114 Sec#150/265 |
| Cash | $32M | US#2,733/3,114 Sec#245/265 |
| Current Ratio | 4.85x | US#494/3,114 Sec#147/265 |
| Performance | ||
| 1Y Return | 50.00% | US#626/3,114 Sec#87/265 |
| 1M Return | -12.72% | US#2,679/3,114 Sec#197/265 |
| From 52W High | -37.31% | US#2,172/3,114 Sec#142/265 |
| 1Y MDD | -42.44% | US#2,048/3,114 Sec#134/265 |
| Trading | ||
| Volume | 1,218,409 shares | US#1,659/3,114 Sec#157/265 |
| Trading Value | $2M | US#2,914/3,114 Sec#243/265 |
| Per Share | ||
| EPS | $-1.05 | US—/3,114 Sec—/265 |
| BPS | $1.28 | US#2,650/3,114 Sec#191/265 |
Company Info
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.